Superko H R
Lawrence Berkeley Laboratory, University of California, Berkeley Lipid Institute, Sequoia Hospital, Redwood City 94062-2799, USA.
Can J Cardiol. 1995 May;11 Suppl C:4C-8C.
Recent advances in lipidology and metabolic aspects of atherosclerosis allow detailed coronary artery disease (CAD) risk assessment that is of clinical relevance. Genetic dyslipidemias can be identified in over 75% of CAD patients and include the atherosclerosis susceptibility trait (low density lipoprotein [LDL] pattern B), hyperapobetalipoproteinemia, lipoprotein (a), apo E isoforms, and lipoprotein susceptibility to oxidative damage. The inherited amino acid disorder homocysteinemia is present in approximately 20% of CAD patients and is easily treated. Recent studies have highlighted significant differences in response to diet and drug therapy that can be predicted based on the presence or absence of these traits.
脂质学和动脉粥样硬化代谢方面的最新进展使具有临床相关性的详细冠状动脉疾病（CAD）风险评估成为可能。超过75%的CAD患者可被识别出遗传性血脂异常，包括动脉粥样硬化易感性特征（低密度脂蛋白[LDL]模式B）、高载脂蛋白血症、脂蛋白（a）、载脂蛋白E异构体以及脂蛋白对氧化损伤的易感性。遗传性氨基酸紊乱高同型半胱氨酸血症存在于约20%的CAD患者中，且易于治疗。最近的研究强调了基于这些特征的有无可预测的饮食和药物治疗反应的显著差异。
